Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Zander
S Aebi
T Pabst
C Renner
C Driessen

Leukemia

Showing results (1-10 of 14) with videos related to

Pageof 2
Sort By:
Leukemia|April 1, 1997
Monoclonal antibodies in the treatment of non-Hodgkin's lymphoma: recent results and future prospectsC Renner, L Trümper, M Pfreundschuh
Leukemia|January 1, 1997
Expression and regulation of G1 cell-cycle inhibitors (p16INK4A, p15INK4B, p18INK4C, p19INK4D) in human acute myeloid leukemia and normal myeloid cellsJ Schwaller, T Pabst, H P Koeffler, et al.
Leukemia|February 20, 2009
Characterization of the ubiquitin-proteasome system in bortezomib-adapted cellsT Rückrich, M Kraus, J Gogel, et al.
Leukemia|October 7, 2006
Activity patterns of proteasome subunits reflect bortezomib sensitivity of hematologic malignancies and are variable in primary human leukemia cellsM Kraus, T Rückrich, M Reich, et al.
Leukemia|July 6, 2017
Carfilzomib resistance due to ABCB1/MDR1 overexpression is overcome by nelfinavir and lopinavir in multiple myelomaA Besse, S C Stolze, L Rasche, et al.
Leukemia|April 28, 2016
Proteasome inhibitor-adapted myeloma cells are largely independent from proteasome activity and show complex proteomic changes, in particular in redox and energy metabolismG P Soriano, L Besse, N Li, et al.
Leukemia|August 13, 2014
Resistance prediction in AML: analysis of 4601 patients from MRC/NCRI, HOVON/SAKK, SWOG and MD Anderson Cancer CenterR B Walter, M Othus, A K Burnett, et al.
Leukemia|December 7, 2017
Outcome of relapsed infant acute lymphoblastic leukemia treated on the interfant-99 protocolE M C Driessen, P de Lorenzo, M Campbell, et al.
Leukemia|July 16, 2016
Comparative value of post-remission treatment in cytogenetically normal AML subclassified by NPM1 and FLT3-ITD allelic ratioJ Versluis, F E M In 't Hout, R Devillier, et al.
Leukemia|December 19, 2017
Prevention and management of adverse events of Novel agents in multiple myeloma: A consensus of the european myeloma networkH Ludwig, M Delforge, T Facon, et al.
Pageof 2

Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Leukemia|April 1, 1997
Monoclonal antibodies in the treatment of non-Hodgkin's lymphoma: recent results and future prospectsC Renner, L Trümper, M Pfreundschuh
Leukemia|January 1, 1997
Expression and regulation of G1 cell-cycle inhibitors (p16INK4A, p15INK4B, p18INK4C, p19INK4D) in human acute myeloid leukemia and normal myeloid cellsJ Schwaller, T Pabst, H P Koeffler, et al.
Leukemia|February 20, 2009
Characterization of the ubiquitin-proteasome system in bortezomib-adapted cellsT Rückrich, M Kraus, J Gogel, et al.
Leukemia|October 7, 2006
Activity patterns of proteasome subunits reflect bortezomib sensitivity of hematologic malignancies and are variable in primary human leukemia cellsM Kraus, T Rückrich, M Reich, et al.
Leukemia|July 6, 2017
Carfilzomib resistance due to ABCB1/MDR1 overexpression is overcome by nelfinavir and lopinavir in multiple myelomaA Besse, S C Stolze, L Rasche, et al.
Leukemia|April 28, 2016
Proteasome inhibitor-adapted myeloma cells are largely independent from proteasome activity and show complex proteomic changes, in particular in redox and energy metabolismG P Soriano, L Besse, N Li, et al.
Leukemia|August 13, 2014
Resistance prediction in AML: analysis of 4601 patients from MRC/NCRI, HOVON/SAKK, SWOG and MD Anderson Cancer CenterR B Walter, M Othus, A K Burnett, et al.
Leukemia|December 7, 2017
Outcome of relapsed infant acute lymphoblastic leukemia treated on the interfant-99 protocolE M C Driessen, P de Lorenzo, M Campbell, et al.
Leukemia|July 16, 2016
Comparative value of post-remission treatment in cytogenetically normal AML subclassified by NPM1 and FLT3-ITD allelic ratioJ Versluis, F E M In 't Hout, R Devillier, et al.
Leukemia|December 19, 2017
Prevention and management of adverse events of Novel agents in multiple myeloma: A consensus of the european myeloma networkH Ludwig, M Delforge, T Facon, et al.
Pageof 2